Breast cancer heterogeneity determines cancer progression, treatment effects, and
prognosis. However, the precise mechanism for this heterogeneity remains unknown owing …

Biomarkers play an essential role in the management of patients with invasive breast
cancer. For selecting patients likely to respond to endocrine therapy, both oestrogen …

Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

Traditionally, intertumour heterogeneity in breast cancer has been documented in terms of
different histological subtypes, treatment sensitivity profiles, and clinical outcomes among …

Background In metastatic breast cancer, hormone and/or human epidermal growth factor
receptor 2 (HER2)–targeted therapy decision-making is still largely based on tissue …

In 2010, EUSOMA published a position paper, describing a set of benchmark quality
indicators (QIs) that could be adopted by breast centres to allow standardised auditing and …

Purpose: Positron Emission Tomography (PET) imaging of HER2 expression could
potentially be used to select patients for HER2-targed therapy, predict response based on …

Cell-free DNA (cfDNA) has the potential to inform tumor subtype classification and help
guide clinical precision oncology. Here we develop Griffin, a framework for profiling …

Simple Summary A proportion of breast tumors bear the oncogenic transmembrane tyrosine
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …

Background A biopsy of first recurrence or metastatic disease is recommended to re-
evaluate oestrogen receptor status in patients with breast cancer and to select appropriate …